SUPPORTO OMERO PROSSIMALE (SX) 180 MM

Informazioni principali

  • Nome commerciale:
  • SUPPORTO OMERO PROSSIMALE (SX) 180 MM
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • SUPPORTO OMERO PROSSIMALE (SX) 180 MM
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • PLACCHE PER OSTEOSINTESI - ALTRE

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 13-11-2009
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

13-11-2018

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

On September 26, 2018 Oscor notified customers of a recall for certain lots (Recall No. 1035166- 09/07/2018-01-R) of TB Unshrouded Bipolar Pacing Leads. As part of the recall correction activities, Oscor is retrieving any remaining inventory out in the field. The recall scope is being expanded to include expired inventory for devices distributed between December 21, 2011 to May 17, 2018. The recall expansion is to ensure proper disposition of expired units. The FDA has been notified and is aware Oscor In...

FDA - U.S. Food and Drug Administration

30-10-2018

Donorweek 2018: Orgaandonor worden. Dat doe je voor elkaar

Donorweek 2018: Orgaandonor worden. Dat doe je voor elkaar

De donorweek is gestart. Minister Bruno Bruins (Medische Zorg) heeft in dat kader een bezoek gebracht aan de Goudse Scholengemeenschap, Leo Vroman. Tijdens de donorweek is er aandacht voor orgaandonatie en de oproep om te registreren als orgaandonor. Op dit moment staan er nog ruim 1800 patiënten op de wachtlijst voor een orgaan.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

24-10-2018

Cub Cadet LLC recalls Cub Cadet RZT SX EFI Zero-Turn Riding Mower

Cub Cadet LLC recalls Cub Cadet RZT SX EFI Zero-Turn Riding Mower

The fill neck on the top of the fuel tank assembly of the affected mowers can experience stress cracking. This condition can cause fuel to leak from the fill neck during refilling or for the fill neck to shear off from the top of the fuel tank, posing a fire hazard.

Health Canada

27-9-2018

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

During the use of some TB - Temporary Bipolar Pacing Leads, featuring the 2mm unshrouded connectors, the connector cap housing (see Picture 1, No. 2 Pin Cap and Cover) may slide and potentially expose the connection wire. In some instances, this may cause the wire to be more susceptible to loss of connectivity or breakage during movement of the cables causing interruption of the pacing system. The analysis of the returned devices attributed the failure to a design change of the cap housing of the pins. ...

FDA - U.S. Food and Drug Administration

21-6-2018

Gaia Ethnobotanical, LLC., Voluntarily Recalls Kratom Products Due to Potential Salmonella Contamination

Gaia Ethnobotanical, LLC., Voluntarily Recalls Kratom Products Due to Potential Salmonella Contamination

Gaia Ethnobotanical, LLC., is voluntarily recalling all kratom (mitragyna speciosa) powder products, with Lot No.: 0102031800 it manufactured, processed, packed, and/or held, between March 18, 2018 to March 30, 2018 to the consumer level. The products have been found by the U.S. Food and Drug Administration (“FDA”) via sample testing and finding to have salmonella contamination. In lieu of such FDA findings the company has implemented standard operating procedures and sterilization processes in accordanc...

FDA - U.S. Food and Drug Administration

18-1-2019


Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Europe - EMA - European Medicines Agency

10-1-2019


BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00000304/201803

BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000304/201803

BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000304/201803

Europe - EMA - European Medicines Agency

10-1-2019


BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

Europe - EMA - European Medicines Agency

10-1-2019


Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Europe - EMA - European Medicines Agency

10-1-2019


Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Europe - EMA - European Medicines Agency

19-12-2018


Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Europe - EMA - European Medicines Agency

18-12-2018


Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Europe - EMA - European Medicines Agency

18-12-2018


Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Europe - EMA - European Medicines Agency

13-12-2018

voriconazole

voriconazole

voriconazole (Active substance: voriconazole) - Centralised - Art 28 - (PSUR - Commission Decision (2018)8915 of Thu, 13 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/3127/201802

Europe -DG Health and Food Safety

12-12-2018


Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804

Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804

Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804

Europe - EMA - European Medicines Agency

11-12-2018


Ofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00002204/201804

Ofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00002204/201804

Ofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00002204/201804

Europe - EMA - European Medicines Agency

11-12-2018


Felodipine / ramipril: List of nationally authorised medicinal products - PSUSA/00001358/201803

Felodipine / ramipril: List of nationally authorised medicinal products - PSUSA/00001358/201803

Felodipine / ramipril: List of nationally authorised medicinal products - PSUSA/00001358/201803

Europe - EMA - European Medicines Agency

11-12-2018


Methylphenobarbital: List of nationally authorised medicinal products - PSUSA/00002025/201803

Methylphenobarbital: List of nationally authorised medicinal products - PSUSA/00002025/201803

Methylphenobarbital: List of nationally authorised medicinal products - PSUSA/00002025/201803

Europe - EMA - European Medicines Agency

11-12-2018


Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Europe - EMA - European Medicines Agency

10-12-2018

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)8627 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002422

Europe -DG Health and Food Safety

10-12-2018


Metamizole: List of nationally authorised medicinal products - PSUSA/00001997/201804

Metamizole: List of nationally authorised medicinal products - PSUSA/00001997/201804

Metamizole: List of nationally authorised medicinal products - PSUSA/00001997/201804

Europe - EMA - European Medicines Agency

7-12-2018


Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/201804

Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/201804

Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/201804

Europe - EMA - European Medicines Agency

7-12-2018


Chlorprothixene: List of nationally authorised medicinal products - PSUSA/00000717/201803

Chlorprothixene: List of nationally authorised medicinal products - PSUSA/00000717/201803

Chlorprothixene: List of nationally authorised medicinal products - PSUSA/00000717/201803

Europe - EMA - European Medicines Agency

7-12-2018


Ofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00002203/201804

Ofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00002203/201804

Ofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00002203/201804

Europe - EMA - European Medicines Agency

7-12-2018


Nebivolol: List of nationally authorised medicinal products - PSUSA/00002129/201803

Nebivolol: List of nationally authorised medicinal products - PSUSA/00002129/201803

Nebivolol: List of nationally authorised medicinal products - PSUSA/00002129/201803

Europe - EMA - European Medicines Agency

7-12-2018


Dihydroergotoxine - List of nationally authorised medicinal products - PSUSA/0001079/201804

Dihydroergotoxine - List of nationally authorised medicinal products - PSUSA/0001079/201804

Dihydroergotoxine - List of nationally authorised medicinal products - PSUSA/0001079/201804

Europe - EMA - European Medicines Agency

7-12-2018


Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Europe - EMA - European Medicines Agency

6-12-2018


Amlodipine besilate / ramipril: List of nationally authorised medicinal products - PSUSA/00000181/201803

Amlodipine besilate / ramipril: List of nationally authorised medicinal products - PSUSA/00000181/201803

Amlodipine besilate / ramipril: List of nationally authorised medicinal products - PSUSA/00000181/201803

Europe - EMA - European Medicines Agency

6-12-2018


Human anti-d immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001614/201803

Human anti-d immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001614/201803

Human anti-d immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001614/201803

Europe - EMA - European Medicines Agency

5-12-2018


Foscarnet: List of nationally authorised medicinal products - PSUSA/00001472/201803

Foscarnet: List of nationally authorised medicinal products - PSUSA/00001472/201803

Foscarnet: List of nationally authorised medicinal products - PSUSA/00001472/201803

Europe - EMA - European Medicines Agency

5-12-2018


Cilazapril, cilazapril / hydrochlorothiazide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA-00000749-201802

Cilazapril, cilazapril / hydrochlorothiazide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00000749-201802

Cilazapril, cilazapril / hydrochlorothiazide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00000749-201802

Europe - EMA - European Medicines Agency

5-12-2018


Cilazapril, cilazapril / hydrochlorothiazide: List of nationally authorised medicinal products -  PSUSA-00000749-201802

Cilazapril, cilazapril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA-00000749-201802

Cilazapril, cilazapril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA-00000749-201802

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Darzalex,Daratumumab, decision type: , therapeutic area: , PIP number: P/0180/2018

Opinion/decision on a Paediatric investigation plan (PIP): Darzalex,Daratumumab, decision type: , therapeutic area: , PIP number: P/0180/2018

Opinion/decision on a Paediatric investigation plan (PIP): Darzalex,Daratumumab, decision type: , therapeutic area: , PIP number: P/0180/2018

Europe - EMA - European Medicines Agency

26-11-2018

Erivedge (Roche Registration GmbH)

Erivedge (Roche Registration GmbH)

Erivedge (Active substance: vismodegib) - PSUSA - Modification - Commission Decision (2018)7973 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10140/201801

Europe -DG Health and Food Safety

26-11-2018

Ranexa (Menarini International Operations Luxembourg S.A.)

Ranexa (Menarini International Operations Luxembourg S.A.)

Ranexa (Active substance: ranolazine) - PSUSA - Modification - Commission Decision (2018)7980 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/805/PSUSA/2611/201801

Europe -DG Health and Food Safety

26-11-2018

Efient (Daiichi Sankyo Europe GmbH)

Efient (Daiichi Sankyo Europe GmbH)

Efient (Active substance: prasugrel) - PSUSA - Modification - Commission Decision (2018)7978 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2499/201802

Europe -DG Health and Food Safety

23-11-2018

Orfadin (Swedish Orphan Biovitrum International AB)

Orfadin (Swedish Orphan Biovitrum International AB)

Orfadin (Active substance: Nitisinone) - PSUSA - Modification - Commission Decision (2018)7890 of Fri, 23 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2169/201802

Europe -DG Health and Food Safety

22-11-2018

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Active substance: dexamethasone) - PSUSA - Modification - Commission Decision (2018)7886 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1140/PSUSA/985/201801

Europe -DG Health and Food Safety

22-11-2018

Selincro (H. Lundbeck A/S)

Selincro (H. Lundbeck A/S)

Selincro (Active substance: nalmefene) - PSUSA - Modification - Commission Decision (2018)7889 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10120/201802

Europe -DG Health and Food Safety

15-11-2018

alitretinoin

alitretinoin

alitretinoin (Active substance: alitretinoin) - Centralised - Art 28 - (PSUR - Commission Decision (2018)7675 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/90/201801

Europe -DG Health and Food Safety

23-10-2018

EU/3/16/1804 (Eli Lilly Nederland B.V.)

EU/3/16/1804 (Eli Lilly Nederland B.V.)

EU/3/16/1804 (Active substance: Pegylated recombinant human interleukin-10) - Transfer of orphan designation - Commission Decision (2018)6994 of Tue, 23 Oct 2018

Europe -DG Health and Food Safety

29-8-2018

Cometriq (Ipsen Pharma)

Cometriq (Ipsen Pharma)

Cometriq (Active substance: cabozantinib) - PSUSA - Modification - Commission Decision (2018)5761 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10180/201711

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2067 (Omeros London Limited)

EU/3/18/2067 (Omeros London Limited)

EU/3/18/2067 (Active substance: Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2) - Orphan designation - Commission Decision (2018)5737 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/044/18

Europe -DG Health and Food Safety

6-8-2018

Scientific guideline:  Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

Scientific guideline: Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

The guideline aims to address the use of undetectable minimal residual disease (MRD) as an intermediate efficacy endpoint in controlled randomised clinical studies in patients with multiple myeloma (MM), adequately designed to demonstrate efficacy by relevant hard endpoints. MRD as an endpoint in this context would allow earlier approval of new drugs pending final confirmatory data.

Europe - EMA - European Medicines Agency

11-7-2018

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Active substance: alendronic acid / colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4511 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1180/T/30

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2035 (Hanmi Europe Limited)

EU/3/18/2035 (Hanmi Europe Limited)

EU/3/18/2035 (Active substance: Efpegsomatropin) - Orphan designation - Commission Decision (2018)4180 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/18

Europe -DG Health and Food Safety

12-6-2018

EU/3/16/1802 (Quality Regulatory Clinical Ireland Limited)

EU/3/16/1802 (Quality Regulatory Clinical Ireland Limited)

EU/3/16/1802 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)3805 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/197/16/T/01

Europe -DG Health and Food Safety